Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4

被引:36
|
作者
Regev-Shoshani, G
Shoseyov, O
Kerem, Z
机构
[1] Hebrew Univ Jerusalem, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel
[2] Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Robert H Smith Inst Plant Sci & Genet Agr, IL-76100 Rehovot, Israel
关键词
resveratrol; CYP3A4; piceid; kinetics; cyclosporine; polyphenols;
D O I
10.1016/j.bbrc.2004.08.141
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Resveratrol, a polyphenol found in red wine, was recently suggested to act as an irreversible, mechanism-based inactivator of cytochrome P450 3A4 (CYP3A4). We found a significant inhibition of human CYP3A4-dependent transformation of cyclosporine by resveratrol, with IC50 = 4.5 muM. We studied the kinetics parameters of CYP3A4 transformation of resveratrol and structurally related, naturally occurring stilbenes. Resveratrol, piceid, resveratroloside, 5,4'-dihydroxy-3-O-methoxystilbene, and 5,3-dihydroxy-4'-O-methoxystilbene were all shown to inhibit hydroxylation of testosterone by CYP3A4. Both methoxy-stilbenes had lower IC50 values, ranging from 0.43 to 0.47 muM, suggesting that lipophilicity rather than number or positions of free hydroxyls (3,5 or 5,4') determines the CYP3A4 inhibition capacity of polyphenols. In line with these findings, both glucosyl-stilbenes were found to be weak inhibitors of CYP3A4. The affinity of the enzyme towards methoxy-stilbenes, expressed as apparent K-m, was indeed higher than those for the parent resveratrol and its glucosides, in CYP3A4 reaction mixtures. V-max values were similar, except for piceid. These results support the role of lipophilicity in the interaction of polyphenols with CYP3A4. It is suggested that selective structural modifications of substrates add significantly to knowledge acquired through molecular modifications of the enzyme. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:668 / 673
页数:6
相关论文
共 50 条
  • [21] Kinetics of electron transfer between NADPH-cytochrome P450 reductase and cytochrome P450 3A4
    Farooq, Yassar
    Roberts, Gordon C. K.
    BIOCHEMICAL JOURNAL, 2010, 432 : 485 - 493
  • [22] Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions
    Tang, W
    Stearns, RA
    CURRENT DRUG METABOLISM, 2001, 2 (02) : 185 - 198
  • [23] Anthocyanins and their metabolites are weak inhibitors of cytochrome P450 3A4
    Dreiseitel, Andrea
    Schreier, Peter
    Oehme, Anett
    Locher, Sanja
    Hajak, Goeran
    Sand, Philipp G.
    MOLECULAR NUTRITION & FOOD RESEARCH, 2008, 52 (12) : 1428 - 1433
  • [24] Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4
    Isin, EM
    Guengerich, FP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (14) : 9127 - 9136
  • [25] Regioselectivity preference of testosterone hydroxylation by cytochrome P450 3A4
    Yan Zhang
    Phani Morisetti
    Jeffery Kim
    Lynelle Smith
    Hai Lin
    Theoretical Chemistry Accounts, 2008, 121 : 313 - 319
  • [26] Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
    Bottorff, M
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (08): : 1042 - 1043
  • [27] Development of cytochrome P450 3A4 inhibition model.
    Arimoto, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U1019 - U1020
  • [28] QSAR modeling of in vitro inhibition of cytochrome P450 3A4*
    Mao, Boryeu
    Gozalbes, Rafael
    Barbosa, Frederique
    Migeon, Jacques
    Merrick, Sandra
    Kamm, Kelly
    Wong, Eric
    Costales, Chester
    Shi, Wei
    Wu, Cheryl
    Froloff, Nicolas
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2006, 46 (05) : 2125 - 2134
  • [29] Taurine modulates catalytic activity of cytochrome P450 3A4
    Shumyantseva, V. V.
    Makhova, A. A.
    Bulko, T. V.
    Bernhardt, R.
    Kuzikov, A. V.
    Shich, E. V.
    Kukes, V. G.
    Archakov, A. I.
    BIOCHEMISTRY-MOSCOW, 2015, 80 (03) : 366 - 373
  • [30] Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel
    Engels, FK
    ten Tije, AJ
    Baker, SD
    Lee, CKK
    Loos, WJ
    Vulto, AG
    Verweij, J
    Sparreboom, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) : 448 - 454